Invivyd Inc. Expands Focus with New Measles Antibody Program and Investor Engagement

WALTHAM, Mass., May 13, 2025 — Invivyd, Inc. (Nasdaq: IVVD), a biotechnology company specializing in next-generation antibodies for COVID-19 prevention and treatment, has announced significant developments in its research and investor relations activities.

New Measles Antibody Discovery Program

Invivyd has launched a new pipeline discovery program focused on developing a monoclonal antibody treatment for measles. This initiative marks a strategic expansion of the company’s research efforts beyond its existing COVID-19 projects. The program aims to address the growing need for effective treatments against measles, a disease that continues to pose global health challenges.

The company’s announcement has garnered attention from retail traders, who are optimistic about the potential impact of this new program on the future of medicine. The development of a measles monoclonal antibody could position Invivyd as a leader in infectious disease treatment, complementing its ongoing work on COVID-19.

Investor Engagement at BioConnect Conference

In addition to its research advancements, Invivyd is set to participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. Scheduled for Tuesday, May 20, 2025, at 11:00 a.m. ET in New York, NY, the company’s management will engage in a fireside chat and host investor meetings. This event provides an opportunity for Invivyd to present its latest developments and strategic vision to investors and stakeholders.

The conference participation underscores Invivyd’s commitment to transparency and investor relations, as it seeks to build confidence in its growth trajectory and research initiatives.

Financial Overview

As of May 8, 2025, Invivyd’s stock closed at $0.646, reflecting a significant decrease from its 52-week high of $2.74 on February 5, 2025. The stock’s 52-week low was $0.3546, recorded on January 29, 2025. Despite recent volatility, the company’s strategic initiatives and investor engagement efforts may influence future stock performance.

Invivyd continues to serve a global customer base, with its stock traded on the Nasdaq. For more information, stakeholders can visit the company’s official website at www.invivyd.com .

These developments highlight Invivyd’s proactive approach to expanding its research portfolio and strengthening investor relations, positioning the company for potential growth in the biotechnology sector.